• New Data Suggest Early Breast Cancer Treatment Standard
    on March 22, 2019 at 5:00 am

    A new standard may be emerging that substitutes adjuvant T-DM1 for adjuvant trastuzumab in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab, according to results from a phase 3 trial presented at the San Antonio Breast Cancer Symposium. […]

  • Exploring the Role of Cytoreductive Nephrectomy in RCC
    on March 21, 2019 at 9:35 pm

    Brian M. Shuch, MD, highlights the complex data with cytoreductive nephrectomy in renal cell carcinoma and offers advice on how to navigate the intricate treatment landscape. […]

  • Leveraging Limited Data in Metastatic Pancreatic Cancer
    on March 21, 2019 at 8:53 pm

    Damian Laber, MD, provides a brief history of the trials that led to current frontline and second-line standards for patients with metastatic pancreatic cancer and shares his hope for the future of the treatment paradigm. […]

  • Hurvitz Highlights Emerging Agents for Heavily Pretreated HER2+ Breast Cancer
    on March 21, 2019 at 4:29 pm

    Sara A. Hurvitz, MD, discusses recent updates in the paradigm and promising therapeutic strategies on the horizon for patients with HER2-positive metastatic breast cancer. […]

  • GI Oncologist Sheds Light on Present and Future of mCRC Treatment
    on March 21, 2019 at 4:02 pm

    Amit Mahipal, MBBS, discusses navigating the complex treatment paradigm of metastatic colorectal cancer and sheds light on how recent advances are impacting the outlook of those affected by the disease. […]

  • Childhood Cancer Substantially Underdiagnosed Worldwide
    on March 21, 2019 at 3:26 pm

    Childhood cancer is significantly underdiagnosed—especially in south Asia and sub-Saharan Africa—underscoring the need for stronger health systems and the expansion of universal health coverage, according to an analysis published in Lancet Oncology. […]

  • Novel Drug Targets Stem Cell Activity in Pancreatic Cancer
    on March 21, 2019 at 1:54 pm

    Napabucasin, a novel therapy that targets cancer stem cell pathways, is being investigated in a phase III clinical trial that is believed to be the largest study ever conducted in pancreatic ductal adenocarcinoma in the metastatic setting […]

  • EU Approves Keytruda/Chemo Combo to Treat Metastatic Squamous NSCLC
    by admin on March 20, 2019 at 7:23 pm

    This post was originally published on this site The European Commission has approved a combination of Keytruda (pembrolizumab) plus standard chemotherapy for the initial treatment of metastatic squamous non-small cell lung cancer (NSCLC), Merck (known as MSD outside the U.S. and Canada) announced. The approval — which makes the combination available in all 28 member […] The post EU Approves Keytruda/Chemo Combo to Treat Metastatic Squamous NSCLC appeared first on BioNewsFeeds. […]

  • Despite Progress in Follicular Lymphoma and MCL, Critical Questions Remain
    on March 20, 2019 at 7:23 pm

    Izidore S. Lossos, MD, discusses the current pillars of care and barriers in the treatment of patients with early-stage and advanced follicular lymphoma, as well as mantle cell lymphoma. […]

  • Atezolizumab Combo Regimen Approved for ES-SCLC
    on March 20, 2019 at 6:30 pm

    Atezolizumab (Tecentriq, Genentech) is the first new treatment option for this type of lung cancer in more than 20 years, according to the FDA. […]

  • Sznol Highlights Immunotherapy Advances in RCC
    on March 20, 2019 at 5:45 pm

    Mario Sznol, MD, highlights recent advances made with immunotherapy in renal cell carcinoma and sheds light on what the future may hold. […]

  • Immunotherapy Combos May Mark Future of Gastric Cancer Care
    on March 20, 2019 at 4:21 pm

    Rutika Mehta, MD, MPH, discusses the current gastric cancer treatment landscape and sheds light on how emerging therapies could impact the paradigm. […]